Oral Cancer Immunotherapy through a Simvastatin‐Loaded Colloidal Dispersion System for the Generation of Sustained Antitumor Immunity

2021 ◽  
Vol 4 (11) ◽  
pp. 2100187
Author(s):  
Seong A. Kim ◽  
Gi‐hoon Nam ◽  
Young Rang Bae ◽  
Saurav Kumar Jha ◽  
Seohyun Kim ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Cancer Immunotherapy ◽  
Antitumor Immunity ◽  
Colloidal Dispersion ◽  
Dispersion System

Oral Cancer Immunotherapy through a Simvastatin‐Loaded Colloidal Dispersion System for the Generation of Sustained Antitumor Immunity

2021 ◽  
pp. 2100025
Author(s):  
Seong A Kim ◽  
Gi‐hoon Nam ◽  
Young Rang Bae ◽  
Saurav Kumar Jha ◽  
Seohyun Kim ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Cancer Immunotherapy ◽  
Antitumor Immunity ◽  
Colloidal Dispersion ◽  
Dispersion System

scholarly journals Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Xiaoping Wang ◽  
Qiaoxia Wang
Keyword(s):  
Liver Cancer ◽  
Cancer Immunotherapy ◽  
Antitumor Immunity ◽  
Immune Cell ◽  
Diagnostic Marker ◽  
Peptide Vaccine ◽  
Alpha Fetoprotein ◽  
Cell Vaccine ◽  
Biological Functions

Hepatocarcinoma is one of the most prevalent gastroenterological cancers in the world with less effective therapy. As an oncofetal antigen and diagnostic marker for liver cancer, alpha-fetoprotein (AFP) possesses a variety of biological functions. Except for its diagnosis in liver cancer, AFP has become a target for liver cancer immunotherapy. Although the immunogenicity of AFP is weak and it could induce the immune escapes through inhibiting the function of dendritic cells, natural killer cells, and T lymphocytes, AFP has attracted more attention in liver cancer immunotherapy. By in vitro modification, the immunogenicity and immune response of AFP could be enhanced. AFP-modified immune cell vaccine or peptide vaccine has displayed the specific antitumor immunity against AFP-positive tumor cells and laid a better foundation for the immunotherapy of liver cancer.

Fusion Hybrid of Dendritic Cells and Engineered Tumor Cells Expressing Interleukin-12 Induces Type 1 Immune Responses against Tumor

2005 ◽  
Vol 91 (6) ◽  
pp. 531-538 ◽  
Author(s):  
Meiqing Shi ◽  
Liping Su ◽  
Sigou Hao ◽  
Xulin Guo ◽  
Jim Xiang
Keyword(s):  
Cancer Immunotherapy ◽  
Tumor Cells ◽  
Antitumor Immunity ◽  
Cytotoxic T Lymphocyte ◽  
Tumor Regression ◽  
Interleukin 12 ◽  
Myeloma Cells ◽  
Th1 Cytokine

Aims and Background Dendritic cell (DC)-tumor fusion hybrid vaccinees that facilitate antigen presentation represent a novel powerful strategy in cancer immunotherapy. Preclinical studies have demonstrated that IL-12 promotes specific antitumor immunity mediated by T cells in several types of tumors. In the present study, we investigated the antitumor immunity derived from vaccination of fusion hybrids between DCs and engineered J558/IL-12 myeloma cells secreting Th1 cytokine IL-12. Methods The expression vector pcDNA-IL-12 was generated and transfected into J558 myeloma cells and then bone marrow-derived DCs were fused with engineered J558/IL-12 cells. The antitumor immunity derived from vaccination of the fusion hybrid DC/J558/IL-12 was evaluated in vitro and in vivo. Results DC/J558/IL-12 cells secreted recombinant IL-12 (1.6 ng/mL), and inoculation of BALB/c mice with DC/J558/IL-12 hybrid induced a Th1 dominant immune response and resulted in tumor regression. Immunization of mice with engineered DC/J558/IL-12 hybrid elicited stronger J558 tumor-specific cytotoxic T lymphocyte (CTL) responses in vitro as well as more potent protective immunity against J558 tumor challenge in vivo than immunization with the mixture of DCs and J558/IL-12, J558/IL-12 and J558, respectively. Furthermore, the antitumor immunity mediated by DC/J558/1L-12 tumor cell vaccination in vivo appeared to be dependent on CD8+ CTL. Conclusions These results demonstrate that the engineered fusion hybrid vaccines that combine Th1 cytokine gene-modified tumor cells with DCs may be an attractive strategy for cancer immunotherapy.

scholarly journals Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapy

2014 ◽  
Vol 10 (11) ◽  
pp. 3214-3223 ◽  
Author(s):  
Kue Peng Lim ◽  
Nicole Ai Leng Chun ◽  
Chai Phei Gan ◽  
Soo-Hwang Teo ◽  
Zainal Ariff Abdul Rahman ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Cancer Immunotherapy ◽  
Vaccine Development

scholarly journals Listeria monocytogenes as a Vector for Cancer Immunotherapy: Current Understanding and Progress

Vaccines ◽  
2018 ◽  
Vol 6 (3) ◽  
pp. 48 ◽  
Author(s):  
John Flickinger ◽  
Ulrich Rodeck ◽  
Adam Snook
Keyword(s):  
Clinical Trials ◽  
Listeria Monocytogenes ◽  
Immune Responses ◽  
Cancer Immunotherapy ◽  
Cancer Vaccines ◽  
Anaerobic Bacterium ◽  
Antitumor Immunity ◽  
Current Understanding ◽  
Current State ◽  
Facultative Anaerobic

Listeria monocytogenes, a Gram-positive facultative anaerobic bacterium, is becoming a popular vector for cancer immunotherapy. Indeed, multiple vaccines have been developed utilizing modified Listeria as a tool for generating immune responses against a variety of cancers. Moreover, over a dozen clinical trials testing Listeria cancer vaccines are currently underway, which will help to understand the utility of Listeria vaccines in cancer immunotherapy. This review aims to summarize current views on how Listeria-based vaccines induce potent antitumor immunity and the current state of Listeria-based cancer vaccines in clinical trials.

scholarly journals Targeting ubiquitin signaling for cancer immunotherapy

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Xiaofei Zhou ◽  
Shao-Cong Sun
Keyword(s):  
Cancer Immunotherapy ◽  
Immune Cells ◽  
Protein Modification ◽  
Antitumor Immunity ◽  
Checkpoint Inhibitors ◽  
Therapeutic Approaches ◽  
Protein Ubiquitination ◽  
Advanced Malignancies ◽  
Novel Targets ◽  
Made In

AbstractCancer immunotherapy has become an attractive approach of cancer treatment with tremendous success in treating various advanced malignancies. The development and clinical application of immune checkpoint inhibitors represent one of the most extraordinary accomplishments in cancer immunotherapy. In addition, considerable progress is being made in understanding the mechanism of antitumor immunity and characterizing novel targets for developing additional therapeutic approaches. One active area of investigation is protein ubiquitination, a post-translational mechanism of protein modification that regulates the function of diverse immune cells in antitumor immunity. Accumulating studies suggest that E3 ubiquitin ligases and deubiquitinases form a family of potential targets to be exploited for enhancing antitumor immunity in cancer immunotherapy.

Sustained Antitumor Immunity Based on Persistent Luminescence Nanoparticles for Cancer Immunotherapy

2021 ◽  
pp. 2106884
Author(s):  
Ruoping Wang ◽  
Junpeng Shi ◽  
Liang Song ◽  
Shenghui Zheng ◽  
Xiaolong Liu ◽  
...  
Keyword(s):  
Cancer Immunotherapy ◽  
Antitumor Immunity ◽  
Persistent Luminescence

Molecular and nanoengineering approaches towards activatable cancer immunotherapy

2020 ◽  
Vol 49 (13) ◽  
pp. 4234-4253 ◽  
Author(s):  
Chi Zhang ◽  
Kanyi Pu
Keyword(s):  
Adverse Events ◽  
Cancer Immunotherapy ◽  
Antitumor Immunity ◽  
Response Rates ◽  
Patient Response ◽  
External Stimuli

This review summarizes the development of activatable immunotherapeutic nanoagents that activate antitumor immunity only in response to internal or external stimuli, which potentially enhance patient response rates while reducing immune-related adverse events during cancer immunotherapy.

scholarly journals Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients

2020 ◽  
Vol 69 (10) ◽  
pp. 2001-2007
Author(s):  
Kayoko Waki ◽  
Kanako Yokomizo ◽  
Kouichiro Kawano ◽  
Naotake Tsuda ◽  
Nobukazu Komatsu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Immune Responses ◽  
Cancer Immunotherapy ◽  
Antitumor Immunity ◽  
Apoptotic Cell ◽  
Recurrent Ovarian Cancer ◽  
Vaccine Therapy ◽  
Plasma Dna ◽  
Necrotic Cell ◽  
Clinical Benefits

Abstract Cancer immunotherapy including vaccine therapy is a promising modality for cancer treatment, but few patients show its clinical benefits currently. The identification of biomarkers that can identify patients who will benefit from cancer immunotherapy is thus important. Here, we investigated the potential utility of the circulating cell-free DNA (cfDNA) integrity—a ratio of necrotic cell-derived, longer DNA fragments versus apoptotic cell-derived shorter fragments of Alu gene—as a biomarker of vaccine therapy for patients with ovarian cancer. We analyzed plasma samples from 39 patients with advanced or recurrent ovarian cancer enrolled in clinical trials for personalized peptide vaccinations. We observed that (1) the cfDNA integrity was decreased after the first cycle of vaccination, and (2) the decreased levels of cfDNA integrity were correlated with vaccine-induced immune responses; i.e., decreased cfDNA integrity was observed in 91.7% and 59.3% of the IgG-positive and negative patients, respectively (p = 0.0445). Similarly, decreased cfDNA integrity was observed in 92.9% and 56.0% of CTL response-positive and negative patients, respectively (p = 0.0283). These results suggest that the circulating cfDNA integrity is a possible biomarker for cancer vaccine therapy.

Sign in / Sign up

Export Citation Format

Share Document